PCM
LGND icon

Parsons Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Parsons Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,619
Closed -$255K – 336
2020
Q1 		$255K Sell
5,619
-553
-9% -$31.3K 0.03% 272
2019
Q4 		$402K Hold
6,172
– – 0.04% 265
2019
Q3 		$383K Sell
6,172
-160
-3% -$10K 0.04% 264
2019
Q2 		$451K Sell
6,332
-72
-1% -$5.3K 0.05% 250
2019
Q1 		$502K Buy
6,404
+48
+0.8% +$3.64K 0.05% 240
2018
Q4 		$538K Buy
6,356
+569
+10% +$60.7K 0.07% 223
2018
Q3 		$991K Hold
5,787
– – 0.1% 183
2018
Q2 		$748K Sell
5,787
-91
-2% -$10.2K 0.08% 212
2018
Q1 		$606K Hold
5,878
– – 0.07% 231
2017
Q4 		$502K Hold
5,878
– – 0.06% 262
2017
Q3 		$499K Hold
5,878
– – 0.06% 247
2017
Q2 		$445K Hold
5,878
– – 0.05% 256
2017
Q1 		$388K Sell
5,878
-1,804
-23% -$119K 0.05% 266
2016
Q4 		$487K Sell
7,682
-200
-3% -$12.6K 0.06% 228
2016
Q3 		$502K Buy
7,882
+4,924
+166% +$362K 0.07% 224
2016
Q2 		$220K Buy
+2,958
New +$220K 0.03% 305

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Parsons Capital Management's LGND Position: Q2 2020 in Review

Parsons Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2020, closing a stake of 5,619 shares — an estimated $255K sold.

Parsons Capital Management first reported a position in LGND in Q2 2016 and held it in 16 quarters. The position peaked at $991K in Q3 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q2 2020.

  • Parsons Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Parsons Capital Management sold 5,619 Ligand Pharmaceuticals shares in Q2 2020, an estimated $255K.
  • Parsons Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 16 quarters.
  • Parsons Capital Management's Ligand Pharmaceuticals position peaked at $991K in Q3 2018.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2020.

Based on Parsons Capital Management's 13F filing for Q2 2020, filed 10 Aug 2020.